SCHEMBL3859481

SCHEMBL3859481

CCN1CCC(O)(c2ccc(F)c(F)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 10/20 0.48
OPRL1 P41146 3/20 0.42
CCR3 P51677 1/20 0.42
SSTR5 P35346 1/20 0.41
HTR1A P08908 2/20 0.41
DRD1 P21728 2/20 0.41
DRD5 P21918 2/20 0.41
SLC6A2 P23975 2/20 0.41
HTR2A P28223 2/20 0.41
SLC6A4 P31645 2/20 0.41
HTR7 P34969 2/20 0.41
HRH1 P35367 2/20 0.41
DRD3 P35462 2/20 0.41
HTR2B P41595 2/20 0.41
HSD11B1 P28845 1/20 0.41
OPRM1 P35372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3115576 0.91 KDM4E (0.44) DRD2OPRL1CCR3SSTR5HTR1A
SCHEMBL3860349 0.88 DRD2 (0.55) DRD2HTR1ADRD1DRD5SLC6A2
SCHEMBL3857772 0.87 OPRL1 (0.48) DRD2OPRL1CCR3SSTR5HTR1A
SCHEMBL3853387 0.87 OPRL1 (0.51) DRD2OPRL1HTR1ADRD1DRD5
SCHEMBL3857799 0.84 OPRL1 (0.55) DRD2OPRL1HTR1ADRD1DRD5
SCHEMBL1329952 0.84 MC4R (0.39) DRD2SLC6A2SLC6A4HSD11B1
SCHEMBL3854368 0.83 AR (0.42) DRD2OPRL1OPRM1
SCHEMBL3111203 0.82 DRD2 (0.47) DRD2HTR1ADRD1DRD5SLC6A2
SCHEMBL16838117 0.82 SLC6A3 (0.46) DRD2OPRL1SLC6A2SLC6A4OPRM1
SCHEMBL8049113 0.82 DRD2 (0.56) DRD2OPRL1HTR1ADRD1DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070270467-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2007-11-22 US claimed
US-7579474-B2 Substituted piperidines as modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH AB, SVERIGE (DK) 2009-08-25 US disclosed
US-20070270467-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2007-11-22 US disclosed
EP-1765779-A1 NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION A. CARLSSON RESEARCH AB (SE) 2007-03-28 EP disclosed
WO-2005121092-A1 NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION A. CARLSSON RESEARCH AB (SE) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270467-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION DRD2, PRLHR, DRD3 DRD2 1/4885OPRL1 9/4885CCR3 2949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.